Download PDF
TumorDiagnostik & Therapie 2017; 38(06): 368-372
DOI: 10.1055/s-0043-107672
Schwerpunkt Tumoren der Nieren und ableitenden Harnwege
© Georg Thieme Verlag KG Stuttgart · New York

Chemotherapie des Harnblasenkarzinoms

Tobias Steinwender
,
Peter Hammer
Further Information

Publication History

Publication Date:
03 August 2017 (online)

Also available at
    Permissions and Reprints

Die seit Jahren etablierte cisplatinhaltige Chemotherapie spielt beim fortgeschrittenen und metastasierten Harnblasenkarzinom weiterhin eine wichtige Rolle. Aktuelle Studienergebnisse mit verschiedenen Immuncheckpoint-Inhibitoren sind vielversprechend, sodass diese Substanzen die therapeutischen Möglichkeiten erweitern.
 

  • Literatur

  • 1 Zentrum für Krebsregisterdaten im Robert Koch-Institut (Hrsg). Bericht zum Krebsgeschehen in Deutschland 2016. Berlin: 2016
    PubMedGoogle Scholar
  • 2 Humphrey PA, Moch H, Cubilla AL. et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol 2016; 70: 106-119
    CrossrefPubMedGoogle Scholar
  • 3 S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms Langversion1.1, November 2016, AWMF-Registernummer: 032/038OL.
    PubMedGoogle Scholar
  • 4 Abern MR, Owusu RA, Anderson MR. et al. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Canc Netw 2013; 11: 477-484
    CrossrefPubMedGoogle Scholar
  • 5 Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-1970
    CrossrefPubMedGoogle Scholar
  • 6 Kamat AM, Witjes JA, Brausi M. et al. Defining and treating the spectrum of intermediate risknonmuscle invasive bladder cancer. J Urol 2014; 192: 305-315
    CrossrefPubMedGoogle Scholar
  • 7 Retz M, Gschwend J. Medikamentöse Tumortherapie in der Uroonkologie. Berlin Heidelberg: Springer-Verlag; 2010 2. Auflage.
    PubMedGoogle Scholar
  • 8 http://www.auanet.org/guidelines/muscle-invasive-bladder-cancer-new-(2017)
    PubMed
  • 9 Reardon ZD, Patel SG, Zaid HB. et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: A sign of changing tides. Eur Urol 2015; 67: 165-170
    CrossrefPubMedGoogle Scholar
  • 10 Sternberg CN, Yagoda A, Scher HI. et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-2458
    CrossrefPubMedGoogle Scholar
  • 11 von der Maase H, Hansen SW, Roberts JT. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077
    CrossrefPubMedGoogle Scholar
  • 12 Winquist E, Kirchner TS, Segal R. et al. Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004; 171: 561-569
    CrossrefPubMedGoogle Scholar
  • 13 Svatek RS, Shariat SF, Lasky RE. et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 2010; 16: 4461-4467
    CrossrefPubMedGoogle Scholar
  • 14 Sternberg CN, Skoneczna I, Kerst JM. et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 2015; 16: 76-86
    CrossrefPubMedGoogle Scholar
  • 15 James ND, Hussain SA, Hall E. et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012; 366: 1477-1488
    CrossrefPubMedGoogle Scholar
  • 16 Nagao K. The efficacy of trimodal chemoradiotherapy as a bladder-preserving strategy for muscle invasive bladder cancer. J Urol 2017 in press
    PubMedGoogle Scholar
  • 17 Loehrer Sr PJ, Einhorn LH, Elson PJ. et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992; 10: 1066-1067
    CrossrefPubMedGoogle Scholar
  • 18 Bellmunt J, von der Maase H, Mead GM. et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012; 30: 1107-1113
    CrossrefPubMedGoogle Scholar
  • 19 De Santis M, Bellmunt J, Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191-199
    PubMedGoogle Scholar
  • 20 Galsky MD, Hahn NM, Rosenberg J. et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol 2011; 29: 2432-2438
    CrossrefPubMedGoogle Scholar
  • 21 von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 2003; 3: 11-19
    CrossrefPubMedGoogle Scholar
  • 22 Bellmunt J, Ribas A, Eres N. et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997; 80: 1966-1972
    CrossrefPubMedGoogle Scholar
  • 23 Bellmunt J, Théodore C, Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-4461
    CrossrefPubMedGoogle Scholar
  • 24 Ning YM, Suzman D, Maher VE. et al. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy. Oncologist 2017; 22 DOI: 10.1634/theoncologist.2017-0087. [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 25 Roche Media Release, Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer.
    PubMedGoogle Scholar
  • 26 Sharma P, Callahan MK, Bono P. et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016; 17: 1590-1598
    CrossrefPubMedGoogle Scholar
  • 27 Massard C, Gordon MS, Sharma S. et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol 2016; 34: 3119-3125
    CrossrefPubMedGoogle Scholar
  • 28 Heery CR, O'Sullivan-Coyne G, Madan RA. et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 2017; 18: 587-598
    CrossrefPubMedGoogle Scholar
  • 29 Bellmunt J, de Wit R, Vaughn DJ. et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017; 376: 1015-1026
    CrossrefPubMedGoogle Scholar